IronBridge Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

IronBridge Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$2.62M	Buy	+60,400	New	+$2.59M	0.16%	155

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IronBridge Capital Management's NBIX Position: Q1 2017 in Review

IronBridge Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q1 2017: 60,400 shares worth $2.62M. The stake represents 0.16% of the portfolio and ranks #155 among its holdings.

218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

IronBridge Capital Management held 60,400 shares of Neurocrine Biosciences worth $2.62M as of Q1 2017.
Neurocrine Biosciences was a new IronBridge Capital Management position in Q1 2017.
Neurocrine Biosciences made up 0.16% of IronBridge Capital Management's portfolio in Q1 2017, its #155 holding.
218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on IronBridge Capital Management's 13F filing for Q1 2017, filed 10 May 2017.